Orphazyme kicks off Dkr675m IPO in Copenhagen with anchor backing

By Aidan Gregory
06 Nov 2017

Orphazyme, a Danish biotechnology company, has revealed the terms for its IPO on Nasdaq Copenhagen.

The deal, led by Carnegie and Danske Bank as global coordinators, consists of up to 9.4m new shares, at a price range of Dkr64 to Dkr80 a share, making the deal worth up to Dkr690m ($107.97m). There is a greenshoe of 1.4m new shares.

Orphazyme will be valued ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.